Skip to main content
Premium Trial:

Request an Annual Quote

S&P Raises Life Tech Ratings to BBB+

NEW YORK (GenomeWeb News) – Standard & Poor's on Thursday raised Life Technologies' corporate credit rating and the issue-level rating on the firm's secured and unsecured debt to BBB+.

Both ratings were raised from prior BBB ratings. S&P said that the outlook for the Carlsbad, Calif.-based firm is stable.

"The upgrade reflects Life Technologies' track record of steadily reducing debt leverage since its large acquisition of Applied Biosystems in 2008, which brought leverage to 3.6x on a pro forma basis," S&P's credit analyst Rivka Gertzulin said in a statement.

The financial services company said that the investment grade rating assumes that the credit metrics will stay in the range appropriate for its "intermediate" financial risk profile, and added that it sees Life Tech's business risk profile as "satisfactory."

The company has a "well-established, diverse product portfolio, high rate of customer retention, non-cyclical demand, strong operating margins, and a high proportion of recurring revenues," S&P noted. It cautioned, though, that uncertainty around government funding for scientific research and weakness in the European economy remain challenges for Life Tech.

Revenue growth is anticipated to be in the low-single digits during the next two years, driven in the near-term by the launch of "its new gene sequencing machine," S&P said, an apparent reference to Life Tech's Ion Torrent desktop sequencers.

Debt leverage is expected to continue declining "moderately" during the next two years even as the company is expected to use half of its free cash flow for share repurchases. Acquisitions should continue to be moderate, S&P said.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.